On April 28, 2020 CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reported that it will report Q1 2020 financial results after the market close on Tuesday, May 5, 2020 (Press release, Cytosorbents, APR 28, 2020, View Source [SID1234556723]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
CytoSorbents’ management will host a live conference call and presentation webcast that will recount both operational and financial progress during Q1 2020 followed by a question and answer session.
Conference Call Details:
Date:
Tuesday, May 5, 2020
Time:
4:45 PM Eastern
Toll Free:
877-451-6152
International:
201-389-0879
Conference ID:
13701769
Live Presentation Webcast:
It is recommended that participants dial in approximately 10 minutes prior to the start of the call. There will also be a simultaneous live webcast of the conference call that can be accessed through the following audio feed link: View Source
An archived recording of the conference call will be available under the Investor Relations section of the Company’s website at View Source